Curator Dashboard

H. Lee Moffitt Cancer Center & Research Institute has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease. As part of an elite group of National Cancer Institute (NCI) Comprehensive Cancer Centers, Moffitt focuses on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. Since the first patient admission in October 1986, Moffitt physicians, scientists and staff members have worked together to establish a tradition of excellence offered in an atmosphere characterized by kindness, caring and hope. The Cancer Center''s future growth in clinical care and research rests firmly on this tradition and makes possible the changes ahead. The mission of Moffitt Cancer Center is to contribute to the prevention and cure of cancer. Moffitt''s vision is to be the leader in scientific discovery and translation into compassionate care, cures, and prevention of cancer for our community and the world. As it grows to fulfill its mission, the Cancer Center will continue to be distinguished by its compassionate and effective patient care. Moffitt Cancer Center is a not-for-profit institution. It includes private patient rooms, the Southeast''s largest Blood and Marrow Transplant Program, outpatient treatment programs that record more than 320,500 visits a year, the Moffitt Research Center, Moffitt Cancer Center at International Plaza and the Lifetime Cancer Screening & Prevention Center.

• Resource
• SciCrunch
• 16 years ago - by Anonymous

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the central source of comprehensive information on drugs and drug addiction in Europe. It was set up to provide factual, objective, reliable and comparable information concerning drugs, drug addiction and their consequences. Mission and work programme Just over a decade ago, Europes capacity for monitoring its drug problem was extremely limited. National approaches to the topic varied greatly and there was a lack of reliable and comparable information at European level concerning drugs, drug addiction and their consequences. In other words, it was impossible to talk with confidence about patterns and trends in drug use across the EU. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was founded in 1993 to change that. Inaugurated in Lisbon in 1995, the EMCDDA is the hub of drug-related information in the European Union. It exists to provide the EU and its Member States with a factual overview of European drug problems and a common information framework to support the drugs debate. The EMCDDA consists of a 90-strong team of specialists representing some 20 nationalities. Today it offers policy-makers the scientific evidence base they need for drawing up drug laws and strategies and helps professionals and researchers pinpoint best practice and new areas for analysis. Improving the comparability of drug information in the EU is central to the agencys work. To achieve this, the EMCDDA coordinates and relies on a network of some 30 national monitoring centres (Reitox network) to gather and analyse country data according to common data-collection standards and tools. The results of this national monitoring process are fed to the Lisbon centre for analysis and are ultimately released in the Annual report on the state of the drugs problem in Europe one of its many outputs. The EMCDDA has many working partners in Portugal. These include technical bodies primarily the Instituto da droga e da toxicodependncia which furnish the agency with the Portuguese drugs picture, and political bodies which use EMCDDA information when taking decisions on drug-related issues. In addition to cooperating with partners at national level, the EMCDDA also collaborates with its peers worldwide, having signed agreements with European and international organisations working in the drugs field. Over time, the EMCDDA has become not only Europes central reference point on drugs but also a respected authority globally. This interest has been reflected in visits by Heads of State and high-ranking politicians from all world regions and in requests from several non-EU countries for cooperation, whether in the area of technical assistance or the exchange of data and expertise. While the EMCDDA monitors the drug situation today, it is ever vigilant for new drugs and emerging trends that may pose a threat to Europes citizens tomorrow. With the production of cocaine and heroin at historically high levels and with around 7,000 Europeans dying every year of drug overdoses, constant monitoring is imperative. Public access to documents Citizens of the European Union and natural or legal persons residing or having their registered office in a Member State have the right of access to EMCDDA documents under Article 255(1) of the EC Treaty and Article 2(1) of Regulation (EC) No 1049/2001 in accordance with detailed rules laid out in the implementing rules adopted by the Management Board on 24 February 2006. This right to access concerns documents held by the EMCDDA, that is to say, documents drawn up or received by it and in its possession. Pursuant to article 2(2) of Regulation (EC) No 1049/2001, citizens of third countries not residing in a Member State and legal persons not having their registered office in one of the Member States shall enjoy the right of access to EMCDDA documents on the same terms as the beneficiaries referred to in Article 255(1) of the EC Treaty and Article 2(1) of Regulation (EC) No 1049/2001. All applications for access to a document should be sent by mail, fax or email, clearly stating the reference Application for access to EMCDDA documents. Funding The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre''s Director to the Management Board which may modify the draft before adopting it and submitting it to the European Commission. On this basis, the Commission presents its proposal for the annual funding to the EMCDDAs budget, to be adopted by the European Parliament and the Council. The implementation of the EMCDDA budget is subject to the external audit of the European Court of Auditors. The political responsibility for the execution of the budget rests with the EMCDDA''s Management Board, which adopts its own internal financial rules, based on the financial regulation applicable to the general budget of the European Communities.

• Resource
• SciCrunch
• 17 years ago - by Anonymous

Web interactive set of tools for sampling and randomization of data sets and generation of random patterns. The tools include randomization and permutation of data (even stratified random sampling) and random assignments for studies, generation of random numbers following specific probability distributions, generation of random and quasi-random point distributions and sampling patterns, noise in one or two dimensions with adjustable spectral properties, random walks and Lévy flights. Own data tables can be provided for random sampling in a privacy-friendly way, as data processing takes place directly in the browser and no data is transferred to anywhere else. Random Number Lab also offers some educational material and worksheets and can be used for scientific and educational purposes.

• Resource
• RRID
• 9 months ago - by Anonymous

An organization that funds research for Alzheimer's disease, provides information on new treatment strategies, provides information on caring for afflicted people, and generally increases public knowledge of disease prevention. This program financially supports new Alzheimer's studies. These research projects are selected by the Medical and Scientific Advisory Council. The council chooses which studies to address based on their potential uses in diagnostics, genetics, treatments, prevention, early detection and general enhancement of lifestyle.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

We are the center of excellence for research and education on the prevention, understanding, and treatment of PTSD. Our Center has seven divisions across the country. Although we provide no direct clinical care, our purpose is to improve the well-being and understanding of American Veterans. We conduct cutting edge research and apply resultant findings to: Advance the Science and Promote Understanding of Traumatic Stress. The National Center has emerged as the world's leading research and educational center of excellence on PTSD. Its vision is to be the foremost leader in information on PTSD and trauma; information generated internally through its extensive research program, and information synthesized from published scientific research and collective clinical experience that is efficiently disseminated to the field. The Center is organized to facilitate rapid translation of science into practice, assuring that the latest research findings inform clinical care; and translation of practice into science, assuring that questions raised by clinical challenges are addressed using rigorous experimental protocols. By drawing on the specific expertise vested at each separate division (e.g., behavioral, neuroscientific, etc.), the National Center provides a unique infrastructure within which to implement multidisciplinary initiatives regarding the etiology, pathophysiology, diagnosis and treatment of PTSD.

• Resource
• SciCrunch
• 16 years ago - by Anonymous

Provides genomics, proteomics, and bioinformatic services, including next-generation-based genome, microbiome and metagenome sequencing, gene expression and transcriptome analysis, and proteome analysis. CAGEF has established internationally-recognized genomics expertise in the analysis of non-standard species, systems, and environments, with particular experience in microbial, plant, and environmental genomics and metagenomics.

• Resource
• SciCrunch
• 8 months ago - submitted by Edyta Vieth

Open tools to support data management for biological light microscopy produced by a multi-site collaborative effort among academic laboratories and a number of commercial entities. Designed to interact with existing commercial software, all OME formats and software are free, and all OME source code is available under the GNU General public license or through commercial license from Glencoe Software. OME is developed as a joint project between research-active laboratories at the Dundee, NIA Baltimore, and Harvard Medical School and LOCI. In addition, OME has active collaborations with many imaging and informatics groups. While many other applications could use OME''s architecture and design, their specific implementation is focused on biological and biomedical imaging. Those interested in applying OME''s technology to other applications should contact the developers. OME work is divided into several different standards and software projects: * Bio-Formats: A Java-based library for reading and writing over 90 microscopy file formats. * OMERO Software: The Java-based OMERO software project, which currently includes tools for storing, visualizing, managing, and annotating microscopic images and metadata. * OME-XML & OME-TIFF: The OME-XML and OME-TIFF file format specifications, which are open file formats for sharing microscope image data. * OME Server: This was the original OME server project which has now ended and is a legacy product. It implements image-based analysis of cellular dynamics and image-based screening of cellular localization or phenotypes, and included a fully developed version of the 2003 version of OME-XML Schema language.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Research institute which investigates chronic disease and its triggers.

• Resource
• SciCrunch
• 17 years ago - by Anonymous

Public research university with two primary campuses in Fredericton and Saint John, New Brunswick. University founded in 1785, holding the title of Canada's oldest English-language university ranked as the top university in Atlantic Canada and a leader in engineering, computer science, and entrepreneurship.

• Resource
• RRID
• 8 months ago - submitted by Edyta Vieth

A foundation that offers grants for researchers in cardiology, lipid and organ transplant in Washington and Alaska. The Robert B McMillen Foundation is a non-profit charitable foundation established to; promote research in the areas of cardiology, lipid and organ transplant, support education at the university and college level in the states of Washington and Alaska and provide funding for social service organizations. What we fund: * MEDICAL: 50% of our annual giving is earmarked for medical research. We will consider making grants to non-profit organizations involved in researching cardiology, lipid and organ transplants. * EDUCATION: 25% of our annual giving is earmarked for Education at the University level in the states of Washington and Alaska. Funding will be provided to support the art departments of post secondary schools who offer a degree in the visual arts. * SOCIAL: 25% of our annual giving is earmarked for social areas including, but not limited to, Goodwill, Salvation Army & United Way. Preference is given to organizations and/or programs that use art as the vehicle to impact communities and change individual lives.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

A biopharmaceutical company that focuses on central nervous system (CNS) diseases. The company is the result of a merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Elan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases such as addiction, schizophrenia, diabetes and depression. Among these, five products are primary to the company: risperidone Long-Acting Injection (Risperdal Consta) for schizophrenia and bipolar 1 disorder, paliperidone palmitate (Invega Sustenna in the U.S., Xeplion in Europe) for schizophrenia, 4-aminopyridine (Ampyra in the U.S., Fampyra in Europe) to improve walking in patients with multiple sclerosis, naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence, and exenatide extended-release for injectable suspension (Bydureon) for the treatment of type 2 diabetes. Bydureon is a once-weekly, long-acting form of the drug exenatide (Byetta) and was developed through a partnership between Amylin, Alkermes and Eli Lilly. It is approved in Europe and the U.S. (Wikipedia)

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Nextflow pipeline to process whole genome long-read sequencing data generated in the context of ASAP project.

• Resource
• RRID
• 8 months ago - by Anonymous

Collection of legacy literature in biodiversity assembled by an international consortium of natural history and botanical libraries. It also serves as the foundational literature component of the Encyclopedia of Life. Browse by author, title, subject, collection, map, year, language, and contributor. Taxonomic search using UBio. Also supports data export and a variety of machine interfaces.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

An Antibody supplier

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Public institution of higher learning in Kenya, located in Njoro, 24 km from Nakuru city. Founded in 1939 as a farm school by Lord Maurice Egerton, it specializes in agriculture but offers diverse programs across 10 faculties, including Arts, Law, Commerce, Health Sciences, and Engineering.

• Resource
• RRID
• 8 months ago - submitted by Edyta Vieth

A graphic, interactive program to map quantitative trait loci using intercrosses, backcrosses or recombinant inbred strains in experimental plants or animals. A completely rewritten cross-platform version of Map Manager QT with enhanced analysis functions. (entry from Genetic Analysis Software)

• Resource
• SciCrunch
• 14 years ago - by Anonymous

European Commission''s primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Software R package that provides comprehensive computational pipeline for predicting survival probabilities and risk groups in cancer patients. Includes dedicated modules to perform key steps such as data preprocessing, training/test splitting, and normalization.

• Resource
• RRID
• 8 months ago - submitted by Harpreet Kaur

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. Software application that draws genetic linkage maps on PC same as what MAPMAKER does on Mac. (entry from Genetic Analysis Software)

• Resource
• SciCrunch
• 14 years ago - by Anonymous

A government granting agency which consults with partnered programs through national authorities and food safety agencies. EFSA organizes its annual and multi-annual work program according to priorities agreed with the European Commission and other partners, taking into account available resources. EFSA staff may also produce scientific outputs on behalf of the agency, such as peer reviews of the assessment of active substances in pesticides, or responses to urgent requests for advice. EFSA staff also monitor and analyze information and data on biological hazards, chemical contaminants, food consumption and emerging risks.

• Resource
• SciCrunch
• 13 years ago - submitted by Andrea Stagg